Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Masimo (NASDAQ: MASI) has announced significant leadership changes effective February 12, 2025. Katie Szyman, currently worldwide president of Advanced Patient Monitoring at BD, has been appointed as the new CEO. Michelle Brennan, who served as Interim CEO, has been named Chairman of the Board, while Lead Independent Director Quentin Koffey becomes Vice Chairman.
Szyman brings over 35 years of experience, notably leading Edwards Lifesciences' Critical Care product group before its acquisition by BD in September 2024. Her appointment follows an extensive search process by Korn Ferry. The Board selected Szyman for her track record in accelerating revenue growth, experience in bringing new patient monitoring products to market, and success in leading industry talent.
The Board continues its previously announced strategic review of alternatives for both consumer audio and consumer healthcare businesses, with Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as legal advisor.
Outset Medical (Nasdaq: OM), a pioneering medical technology company focused on revolutionizing dialysis through cost and complexity reduction, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chair & CEO Leslie Trigg will deliver a presentation on Wednesday, January 15, 2025, at 8:15 a.m. Pacific time.
Interested parties can access both live and archived versions of the presentation through the company's investor relations website at investors.outsetmedical.com.
Outset Medical (Nasdaq: OM) has announced a significant financial restructuring, including a $168.8 million private placement through the sale of Series A Non-Voting Convertible Preferred Stock at $200.00 per share. The company has also secured a new debt financing of up to $125 million maturing in 2030, which will be used to retire $200 million in prior debt.
The private placement was led by PFM Health Sciences, LP and Perceptive Advisors, with participation from T. Rowe Price Investment Management and other institutional investors. Additionally, board members and management will invest an extra $3.9 million upon shareholder approval.
The company reported unaudited Q4 2024 revenue of $29 million and full-year 2024 revenue of $113 million, exceeding previous guidance. Following the financing and debt repayment, Outset expects to have approximately $210 million in cash and equivalents with $100 million in debt.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its participation in the 2024 Stifel Healthcare Conference. The company's management team will deliver a presentation on Tuesday, November 19, 2024, at 10:20 a.m. Eastern time. Interested parties can access both the live presentation and archived recording through the 'Investors' section of Outset's website at investors.outsetmedical.com.
Outset Medical (Nasdaq: OM) presented new research at Kidney Week 2024 demonstrating significant benefits of their Tablo Hemodialysis System for home hemodialysis patients and caregivers. Two key findings were highlighted: First, patients reported improvements in depression and faster recovery from treatments, with high recommendation scores (NPS of 9.2-9.3). Second, caregivers showed strong confidence in supporting treatments, with 98% feeling confident and 100% satisfied with their role, resulting in high recommendation scores (NPS of 8.9). Additionally, a study in Kidney Medicine provided consensus recommendations for catheter use in home hemodialysis, suggesting individualized approaches for vascular access.
Outset Medical (Nasdaq: OM) announced it will release its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day, featuring Chair and CEO Leslie Trigg and CFO Nabeel Ahmed to discuss financial and operating results. Interested participants can register online to receive dial-in details and a unique pin. A live and archived webcast will be available on the company's investor relations website.
Outset Medical (Nasdaq: OM) reported Q2 2024 financial results, showing mixed performance. Revenue decreased to $27.4 million from $36.0 million in Q2 2023, primarily due to a decline in product revenue. However, recurring revenue from Tablo cartridges and service increased by 24%. The company saw significant improvement in gross margins, with total gross margin rising to 35.7% from 21.4% year-over-year. Operating expenses decreased by 21% to $40.5 million. Net loss narrowed to $34.5 million, or $(0.66) per share. Outset revised its 2024 revenue guidance downward to approximately $110 million, citing lower-than-expected new console placements.
Outset Medical (Nasdaq: OM), a medical technology company focused on reducing dialysis costs and complexity, has announced its plans to release Q2 2024 financial results on Wednesday, August 7, 2024, after market close. The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day to discuss financial and operating results.
The call will be led by Leslie Trigg, Chair and CEO, and Nabeel Ahmed, CFO. Interested participants can register online to receive dial-in numbers and a unique pin. Registration is recommended at least 15 minutes before the call. A live and archived webcast will be available on the company's investor relations website.
Outset Medical (Nasdaq: OM), a medical technology company focused on reducing the cost and complexity of dialysis, will present at the Goldman Sachs 45th Annual Global Healthcare Conference. The presentation is scheduled for June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast will be accessible via the 'Investors' section of the Outset Medical website.
Outset Medical, Inc. reported its financial results for the first quarter of 2024, highlighting revenue of $28.2 million, a 12% growth in service and other revenue, and a total gross margin improvement to 29.2%. Operating expenses decreased by 10% from the prior year. The company remains focused on reducing costs, achieving profitability, and capitalizing on the $11 billion U.S. dialysis market opportunity.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?
How has Outset Medical performed financially?
